Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World December 23, 2013 Jennifer Newton	AstraZeneca claims quashed in heartburn drug patent case An appeals court has ruled in favor of Hanmi Pharmaceuticals in a patent dispute over AstraZeneca's best-selling acid reflux drug Nexium (esomeprazole magnesium).
Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool August 4, 2011 Brian Orelli	Pfizer's Long-Shot Lipitor Gamble Don't count on OTC Lipitor anytime soon.
Chemistry World May 19, 2014 Phillip Broadwith	AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
Chemistry World September 17, 2007	Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing.
The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool November 2, 2011 Brian Orelli	Lipitor Loss Looming, Pfizer Shines Good thing it's already priced in.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool January 20, 2006 Rich Duprey	Generics Give Originators Heartburn Eisai, the Japanese manufacturer of an acid reflux remedy, sees a generic maker win FDA approval. What does this mean for investors?
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool February 29, 2008 Brian Orelli	Merck's Complicated Partnerships Merck has decided to continue its complicated partnership with AstraZeneca for at least a few more years.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool November 23, 2004 Rich Duprey	Backyard Treasure Hunts Not every busy backyard venture will be a profitable seven-bagger investment, but here is some good advice on looking in one's own backyard for investment possibilities.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
The Motley Fool August 3, 2006 S.J. Caplan	AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future.
Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World December 8, 2015 Jennifer Newton	Pfizer to close Cambridge pain outpost Pfizer plans to shut down its Neusentis site on the outskirts of Cambridge, UK, in a move that will eliminate up to 120 jobs.
The Motley Fool April 29, 2009 Brian Orelli	The Other 33.1% of Pfizer Reports The take-home message for current and future Pfizer shareholders from Wyeth's quarterly report is that they're not getting a growth monster, but Wyeth's revenue is fairly stable.
Chemistry World February 2, 2007 Victoria Gill	AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits.
The Motley Fool September 2, 2011 David Williamson	When a Good Idea Goes Bad And with it go AstraZeneca's hopes of differentiation in a generic world.
Chemistry World November 27, 2015 Anthony King	Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes.
The Motley Fool April 19, 2005 Stephen D. Simpson	Pfizer Fosters Fertile Future Results in the "here and now" aren't bad, but it will take a couple of years to build growth. Of course, investors must do their own research and make their own decisions.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
The Motley Fool November 27, 2007 Brian Orelli	Second Chance for Merck's MEVACOR Merck licenses the rights to an over-the-counter version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline, but the deal is far from done. Investors, take note.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool January 27, 2005 Stephen D. Simpson	AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer.
The Motley Fool May 6, 2008 Brian Orelli	Free Drugs Free over-the-counter drugs are a win-win for health insurers and their members.
Chemistry World August 3, 2012 Andrew Turley	Pfizer secures Sandwich buyer Pfizer has found a buyer for its R&D site in Sandwich, UK: the site -- now called Discovery Park -- has been bought by a private consortium, according to Kent County Council.
Chemistry World February 1, 2013 Andrew Turley	Zoetis IPO launches at $2.2bn The separation of Pfizer from its animal health business, Zoetis, has begun. Pfizer has priced its initial public offering of 86 million shares at $26 per share, for a total of $2.2 billion
The Motley Fool July 24, 2008 Brian Lawler	Will Pfizer Pfizzle? The drugmaker posts strong earnings, but the good times may not last.
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
National Real Estate Investor May 6, 2003 Parke Chapman	Pfizer's Expansion to Boost Manhattan Economy Drug maker Pfizer will infuse $1 billion into New York City's ailing economy via the acquisition of a major midtown office building and the subsequent creation of thousands of jobs.
The Motley Fool February 2, 2010 Brian Orelli	Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen.
The Motley Fool January 28, 2008 Brian Orelli	Dr. Reddy's Rough Quarter Dr. Reddy's Laboratories moves manufacturing back to India and moves forward with OTC generic drugs.
The Motley Fool May 3, 2010 Brian Orelli	While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind.